Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus

Sponsored:

Wednesday, July 15, 2026

The pharmaceutical industry loses billions each year on drug candidates that perform well in animal testing but ultimately fail in human trials, most often because of safety concerns. As regulators push for more predictive human-based testing models, companies developing next-generation preclinical technologies are beginning to attract growing attention from both pharmaceutical partners and investors.

Shares of VivoSim Labs, Inc. (Nasdaq: VIVS) are climbing Wednesday after the company announced it received a $5 million milestone payment from Eli Lilly while also issuing fiscal 2027 guidance calling for revenue growth of more than 500%.

The milestone payment stems from an inflammatory bowel disease drug program VivoSim previously developed and sold outright to Eli Lilly (NYSE: LLY). The payment was triggered by the dosing of the first patient in Phase 2 studies of the drug. While Lilly now controls the program's development, VivoSim remains eligible to receive up to an additional $45 million in milestone payments tied to future regulatory and commercial achievements.

The company's growth outlook may be the bigger catalyst. VivoSim expects revenue to increase more than 500% in fiscal 2027 as demand builds for its contract research services built around New Approach Methodologies, or NAMs, using advanced 3D human cellular models. Management said pharmaceutical customers are increasingly adopting the company's technology because of its ability to better predict clinical outcomes before expensive human trials begin.

VivoSim combines primary human cell models with multi-endpoint biological analysis while training AI prediction models on the resulting data. In addition to traditional small molecule drug candidates, the platform is designed to evaluate newer therapeutic modalities, including antibody drug conjugates, antibodies, siRNA, and gene therapies. The goal is to improve the industry's ability to identify safety and efficacy issues before drugs reach clinical development.

Recent validation data reinforces that approach. VivoSim reported its NAMkind™ Liver spheroid model achieved 91% predictive accuracy under repeat-dose conditions, with 90% sensitivity, 95% specificity, and 99% precision. Its multi-endpoint profiling also minimized false negatives while resolving complex toxicity patterns. Meanwhile, the company's NAMkind™ Intestine models demonstrated greater than 90% sensitivity and overall accuracy in predicting drug-induced diarrhea.

The broader regulatory environment also continues to work in VivoSim's favor. The FDA has been actively encouraging pharmaceutical companies to adopt human-relevant NAM technologies as alternatives to traditional animal testing, a shift that is helping accelerate industry demand for advanced preclinical testing platforms like VivoSim's.

Shares of VIVS are up 16.3% at $0.9706 in Wednesday afternoon trading.

Sponsored: